Argus upgraded shares of Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) from a hold rating to a buy rating in a report released on Friday,TheFlyOnTheWall.com reports. Argus currently has $58.00 price objective on the stock. The analysts noted that the move was a valuation call. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) net profit margin is 6.80% and weekly performance is -1.60%. On last trading day company shares ended up $51.12. Analysts mean target price for the company is $55.91. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) distance from 50-day simple moving average (SMA50) is 1.31%.
On June 6, Barnes & Noble, Inc. (NYSE:BKS) the nation’s largest retail bookseller and the leading retailer of content, digital media and educational products, announced the best gift ideas and offers for Father’s Day, including an exciting low price on NOOK GlowLight, 50% off annual digital subscriptions to more than 20 Time Inc. magazine titles, 40% off all Blu-rays and Jazz CDs, and much more. Barnes & Noble, Inc. (NYSE:BKS) shares advanced 1.98% in last trading session and ended the day on $20.09. Gross Margin is 26.40 % and its return on assets is -5.80%. Barnes & Noble, Inc. (NYSE:BKS) quarterly performance is -6.43 %.
Halcon Resources Corp (NYSE:HK) provided an operational update related to its 314,000 net acre position in the Tuscaloosa Marine Shale (“TMS”). The Horseshoe Hill 11-22H-1 (92% WI) well in Wilkinson County, Mississippi, achieved a 24-hour average initial production rate of 1,208 barrels of oil per day and 1.1 million cubic feet per day of 1,551 BTU natural gas on a 19/64 inch choke. Based on gas composition analysis and assuming full ethane recovery, the Company estimates that the well would produce an additional 212 barrels of NGLs per day for a total 24-hour average initial production rate of 1,548 barrels of oil equivalent per day. Halcon Resources Corp (NYSE:HK) shares moved down -2.81% in last trading session and was closed at $6.22, while trading in range of $6.06 – $6.60. Halcon Resources Corp (NYSE:HK) year to date (YTD) performance is 61.14%.
On June 2, 2014 Orexigen® Therapeutics, Inc. (NASDAQ:OREX) announced that the United States Food and Drug Administration (FDA) has informed the Company that the FDA intends to reassign the Prescription Drug User Fee Act (PDUFA) action date for the NB32 New Drug Application to June 11, 2014, one day beyond the original assignment. The FDA noted that due to an inadvertent administrative error, the Agency had miscalculated the originally assigned PDUFA date.Orexigen Therapeutics, Inc. (NASDAQ:OREX) ended the last trading day at $6.71. Company weekly volatility is calculated as 5.24% and price to cash ratio as 5.03. Orexigen Therapeutics, Inc. (NASDAQ:OREX) showed a positive weekly performance of 7.19%.
BioDelivery Sciences International, Inc. (NASDAQ:BDSI) received approval of the New Drug Application (NDA) for BUNAVAIL™ (buprenorphine and naloxone) buccal film (CIII) from the U.S. Food and Drug Administration (FDA). BUNAVAIL is indicated for the maintenance treatment of opioid dependence and should be used as part of a complete treatment plan to include counseling and psychosocial support. BDSI expects to launch BUNAVAIL late in the third quarter of 2014. BioDelivery Sciences International, Inc. (NASDAQ:BDSI) weekly performance is -1.10 %. On last trading day company shares ended up $9.85. Analysts mean target price for the company is $15.50. BioDelivery Sciences International, Inc. (NASDAQ:BDSI) distance from 50-day simple moving average (SMA50) is 14.09%.